MCID: FML187
MIFTS: 37

Familial Hypertension

Categories: Rare diseases, Genetic diseases, Cardiovascular diseases, Blood diseases

Aliases & Classifications for Familial Hypertension

MalaCards integrated aliases for Familial Hypertension:

Name: Familial Hypertension 50
Genetic Hypertension 69

Classifications:



Summaries for Familial Hypertension

MalaCards based summary : Familial Hypertension, also known as genetic hypertension, is related to pseudohypoaldosteronism, type iie and pseudohypoaldosteronism, type iia. An important gene associated with Familial Hypertension is KLHL3 (Kelch Like Family Member 3), and among its related pathways/superpathways are Ubiquitin mediated proteolysis and Diuretics Pathway, Pharmacodynamics. The drugs Iron and Epoprostenol have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are Increased cell death HMECs cells and cardiovascular system

Related Diseases for Familial Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Familial Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
id Related Disease Score Top Affiliating Genes
1 pseudohypoaldosteronism, type iie 10.7
2 pseudohypoaldosteronism, type iia 10.6 CUL3 KLHL3
3 marden-walker syndrome 10.4 WNK1 WNK4
4 cataract, autosomal dominant congenital 4 10.4 AGT AGTR1
5 potato nose 10.4 AGT AGTR1
6 mental retardation cataracts calcified pinnae myopathy 10.4 AGT AGTR1
7 adenocarcinoma 10.4 AGT AGTR1
8 aortopulmonary window 10.3 AGT AGTR1
9 trichinosis 10.3 AGT AGTR1
10 chylocele of tunica vaginalis 10.3 AGT AGTR1
11 retinitis pigmentosa 17 10.3 AGT AGTR1
12 fibular aplasia ectrodactyly 10.3 AGT AGTR1
13 cascade stomach 10.3 AGT AGTR1
14 renal tubular dysgenesis 10.2 AGT AGTR1
15 microphthalmia, isolated, with coloboma 7 10.2 WNK1 WNK4
16 rhinitis 10.2 KLHL3 WNK1 WNK4
17 laryngostenosis 10.1 AGT AGTR1
18 encephalopathy due to defective mitochondrial and peroxisomal fission 2 10.1 CUL3 KLHL3 WNK4
19 joint disorders 10.1 AGT AGTR1
20 episodic ataxia 10.1 AGT AGTR1
21 congenital bilateral megacalycosis 10.0 AGT AGTR1
22 pulmonary fibrosis 9.8 CUL3 KLHL3 WNK1 WNK4
23 thoracic spinal canal and spinal cord meningioma 9.8 AGT AGTR1
24 hypertension, essential 9.6 AGT AGTR1 WNK1 WNK4
25 myocardial infarction 9.4
26 hypertension and brachydactyly syndrome 9.4
27 pseudohypoaldosteronism 9.4
28 brachydactyly 9.4
29 autosomal dominant polycystic kidney disease 9.4
30 familial isolated pituitary adenoma 6.2 AGT AGTR1 CAND1 COPS8 CUL3 KLHL3

Graphical network of the top 20 diseases related to Familial Hypertension:



Diseases related to Familial Hypertension

Symptoms & Phenotypes for Familial Hypertension

GenomeRNAi Phenotypes related to Familial Hypertension according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.23 CAND1 COPS8 CUL3 KLHL3 RBX1 UBE2M

MGI Mouse Phenotypes related to Familial Hypertension:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.17 AGT AGTR1 CUL3 KLHL3 UBE2M WNK1

Drugs & Therapeutics for Familial Hypertension

Drugs for Familial Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 331)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2 7439-89-6 23925
2
Epoprostenol Approved Phase 4,Phase 3,Phase 2 61849-14-7, 35121-78-9 5280427 5282411
3
Iloprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 78919-13-8 6443959
4
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 171596-29-5 110635
5
Spironolactone Approved Phase 4,Phase 1,Phase 2,Early Phase 1 1952-01-7, 52-01-7 5833
6
Treprostinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 81846-19-7 54786 6918140
7
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147536-97-8 104865
8
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
9
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
10
Amlodipine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 88150-42-9 2162
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Early Phase 1 58-93-5 3639
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Lisinopril Approved, Investigational Phase 4,Phase 2,Phase 1 83915-83-7, 76547-98-3 5362119
15
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
Coal tar Approved Phase 4 8007-45-2
18
Atenolol Approved Phase 4,Early Phase 1 29122-68-7 2249
19
Trichlormethiazide Approved, Vet_approved Phase 4 133-67-5 5560
20
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
21
Propranolol Approved, Investigational Phase 4,Phase 3 525-66-6 4946
22
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
23
Chlorthalidone Approved Phase 4 77-36-1 2732
24
Macitentan Approved Phase 4,Phase 3 441798-33-0
25 Selexipag Approved Phase 4,Phase 3,Phase 2 475086-01-2
26
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
27
Suvorexant Approved Phase 4 1030377-33-3
28
Cilostazol Approved Phase 4 73963-72-1 2754
29
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
30
Angiotensin II Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31 Micronutrients Phase 4,Phase 2
32 Trace Elements Phase 4,Phase 2
33 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
34 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
35 Sildenafil Citrate Phase 4,Phase 2,Phase 3,Phase 1 171599-83-0
36 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Tezosentan Phase 4,Phase 3,Phase 2
38 Vardenafil Dihydrochloride Phase 4,Phase 3
39 diuretics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 1,Phase 2
41 Hormone Antagonists Phase 4,Phase 2,Phase 1
42 Hormones Phase 4,Phase 2,Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
44 Mineralocorticoid Receptor Antagonists Phase 4,Phase 1,Phase 2
45 Mineralocorticoids Phase 4,Phase 1,Phase 2
46 Natriuretic Agents Phase 4,Phase 1,Phase 2,Early Phase 1
47 Sodium Channel Blockers Phase 4,Phase 3,Phase 1
48 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 682)

id Name Status NCT ID Phase Drugs
1 Iron Deficiency In Pulmonary Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
2 Hemodynamic Response After Six Months of Sildenafil Unknown status NCT00483626 Phase 4 oral sildenafil
3 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
4 Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost Unknown status NCT01649739 Phase 4 Levitra
5 Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4 Spironolactone;Placebo
6 Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease Unknown status NCT01383083 Phase 4
7 Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain Unknown status NCT01615627 Phase 4 HypotonicTreprostinil Solution;Eutonic Treprostinil Solution
8 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Unknown status NCT00625469 Phase 4 bosentan
9 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Unknown status NCT00625079 Phase 4 sildenafil;sildenafil
10 Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension Completed NCT01202175 Phase 4 Nebivolol
11 STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia) Completed NCT00637078 Phase 4
12 Bosentan in Treatment of Pulmonary Arterial Hypertension Completed NCT00266162 Phase 4 Bosentan administration
13 Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed NCT00631514 Phase 4 acetaminophen;ibuprofen;piroxicam
14 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
15 Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 Completed NCT01105117 Phase 4 ACT-385781A (Actelion Epoprostenol);Flolan®
16 Epoprostenol for Injection in Pulmonary Arterial Hypertension Completed NCT01105091 Phase 4 ACT-385781A (Actelion Epoprostenol);Flolan®
17 Comparison of Two Treatment Strategies in Hypertensive Patients Completed NCT00171444 Phase 4
18 An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) Completed NCT01338636 Phase 4 Ambrisentan
19 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) Completed NCT00617305 Phase 4 Ambrisentan;Placebo;Sildenafil;Tadalafil
20 TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) Completed NCT03055221 Phase 4 Intravenous Treprostinil
21 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects Completed NCT00741819 Phase 4 Inhaled treprostinil
22 Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Completed NCT00303459 Phase 4 bosentan;placebo
23 Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension Completed NCT00323297 Phase 4 Bosentan;Bosentan;Sildenafil Citrate
24 Combination Therapy in Pulmonary Arterial Hypertension Completed NCT00433329 Phase 4 Bosentan;Sildenafil
25 Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin) Completed NCT02074449 Phase 4
26 STITCH (Simplified Therapeutic Intervention To Control Hypertension) Completed NCT00129909 Phase 4 fixed dose combination therapy
27 Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Completed NCT02191137 Phase 4 Riociguat (Adempas, BAY63-2521)
28 Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication Completed NCT01268553 Phase 4 Treprostinil
29 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension Completed NCT01330108 Phase 4 ambrisentan
30 Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) Completed NCT02847260 Phase 4 Remodulin
31 Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) Completed NCT00882947 Phase 4 Ventavis (Iloprost, BAYQ6256)
32 Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Completed NCT00317486 Phase 4 bosentan
33 Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) Completed NCT01462565 Phase 4 current marketed FLOLAN (epoprostenol sodium);new thermo stable formulation of epoprostenol sodium
34 BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Completed NCT00367770 Phase 4 Tracleer®
35 A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension Completed NCT00058929 Phase 4 treprostinil sodium
36 Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension Completed NCT00004754 Phase 4 epoprostenol
37 Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics Completed NCT00157638 Phase 4 optimizing therapeutic treatments
38 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
39 Pharmacogenomic Evaluation of Antihypertensive Responses Completed NCT00246519 Phase 4 Hydrochlorothiazide;Atenolol
40 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
41 Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults Completed NCT00439738 Phase 4 HCTZ + Amlodipine;Valsartan/HCTZ
42 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed NCT01042158 Phase 4 tadalafil and ambrisentan upfront combination therapy
43 Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients Completed NCT01190007 Phase 4 Caduet
44 Resistant Arterial Hypertension Cohort Study Recruiting NCT01083017 Phase 4 chlorthalidone;standardized anti-hypertensive treatment
45 The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study Recruiting NCT02253394 Phase 4 Ambrisentan plus Spironolactone;Ambrisentan plus Placebo
46 Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) Recruiting NCT02968901 Phase 4 macitentan;tadalafil
47 Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension Recruiting NCT01054105 Phase 4 Iloprost
48 Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy Recruiting NCT02891850 Phase 4 Adempas (Riociguat, BAY63-2521);Sildenafil;Tadalafil
49 Crossover Study From Macitentan or Bosentan Over to Ambrisentan Recruiting NCT02885012 Phase 4 Ambrisentan
50 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Recruiting NCT02310672 Phase 4 Macitentan

Search NIH Clinical Center for Familial Hypertension

Genetic Tests for Familial Hypertension

Anatomical Context for Familial Hypertension

MalaCards organs/tissues related to Familial Hypertension:

39
Heart, Testes, Lung, Liver, Endothelial, Kidney, Bone

Publications for Familial Hypertension

Articles related to Familial Hypertension:

(show all 23)
id Title Authors Year
1
A PDE3A mutation in familial hypertension and brachydactyly syndrome. ( 27053290 )
2016
2
Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia. ( 26286618 )
2015
3
The polymorphism of angiotensin-receptor gene A1166C in familial hypertension and its distribution in the Han Yellow race of China. ( 24145933 )
2013
4
An inducible transgenic mouse model for familial hypertension with hyperkalaemia (Gordon's syndrome or pseudohypoaldosteronism type II). ( 23336180 )
2013
5
Renal FMD may not confer a familial hypertensive risk nor is it caused by ACTA2 mutations. ( 21553326 )
2011
6
The metabolic syndrome and risk of myocardial infarction in familial hypertension (hypertension heredity in MalmAP evaluation study). ( 19050451 )
2009
7
The effects of exercise on haemodynamic function in relation to the familial hypertension risk model. ( 16496017 )
2006
8
Spironolactone responsive familial hypertension. A potentially high prevalence of mineralocorticoid disease in Oman. ( 12682699 )
2003
9
Influence of familial hypertension on blood pressure, serum cholesterol, high density lipoprotein cholesterol during second and third decade of life in Punjabi population. ( 15255633 )
2003
10
High urinary excretion of uric acid combined with high excretion of calcium links kidney stone disease to familial hypertension. ( 11812875 )
2002
11
Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. ( 11243302 )
2001
12
Abnormalities in insulin sensitivity, vascular resistance and erythrocyte cation transport are independent genetic traits in familial hypertension. ( 10451037 )
1999
13
Familial hypertension, insulin, sympathetic activity, and blood pressure elevation. ( 9674644 )
1998
14
Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. ( 7478115 )
1995
15
Familial hypertension and albuminuria in normotensive type I diabetic patients. ( 8282370 )
1994
16
Familial hypertension in Morgagni's De Sedibus et Causis Morborum per Anatomen Indagatis. ( 7847481 )
1994
17
Cross-sectional analysis of Met235-->Thr variant of angiotensinogen gene in severe, familial hypertension. ( 8267622 )
1993
18
Influence of familial hypertension of the donor on the blood pressure and antihypertensive therapy of kidney graft recipients. ( 7050749 )
1982
19
Influence of familial hypertension on blood pressure during adolescence. ( 6975038 )
1981
20
Familial hypertension and hormonal profile, renal haemodynamics and body fluids of young normotensive subjects. ( 282088 )
1978
21
Familial hypertension. ( 1185030 )
1975
22
Chronic hypertension following pre-eclamptic toxaemia: the influence of familial hypertension on its causation. ( 13564280 )
1958
23
Chronic hypertension following pre-eclamptic toxaemia; the influence of familial hypertension on its causation. ( 13367916 )
1956

Variations for Familial Hypertension

Expression for Familial Hypertension

Search GEO for disease gene expression data for Familial Hypertension.

Pathways for Familial Hypertension

Pathways related to Familial Hypertension according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.27 CUL3 RBX1 UBE2M
2 10.62 WNK1 WNK4
3 10.61 AGT AGTR1 PDE3A

GO Terms for Familial Hypertension

Cellular components related to Familial Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.91 AGT CAND1 COPS8 CUL3 KLHL3 RBX1
2 cytosol GO:0005829 9.65 AGT CAND1 COPS8 CUL3 KLHL3 PDE3A
3 Cul3-RING ubiquitin ligase complex GO:0031463 9.33 CUL3 KLHL3 RBX1
4 cullin-RING ubiquitin ligase complex GO:0031461 8.8 CAND1 CUL3 RBX1

Biological processes related to Familial Hypertension according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 protein ubiquitination GO:0016567 9.89 CAND1 CUL3 KLHL3 RBX1 UBE2M
2 protein monoubiquitination GO:0006513 9.61 CUL3 RBX1
3 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 AGT AGTR1
4 regulation of vasoconstriction GO:0019229 9.6 AGT AGTR1
5 nucleotide-excision repair, DNA damage recognition GO:0000715 9.59 COPS8 RBX1
6 protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:0042787 9.58 CUL3 KLHL3
7 positive regulation of cellular protein metabolic process GO:0032270 9.58 AGT AGTR1
8 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.57 AGT AGTR1
9 low-density lipoprotein particle remodeling GO:0034374 9.56 AGT AGTR1
10 protein neddylation GO:0045116 9.55 RBX1 UBE2M
11 positive regulation of cholesterol esterification GO:0010873 9.54 AGT AGTR1
12 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.52 AGT AGTR1
13 SCF complex assembly GO:0010265 9.51 CAND1 RBX1
14 ion homeostasis GO:0050801 9.48 KLHL3 WNK4
15 positive regulation of NAD(P)H oxidase activity GO:0033864 9.46 AGT AGTR1
16 negative regulation of pancreatic juice secretion GO:0090188 9.43 WNK1 WNK4
17 renin-angiotensin regulation of aldosterone production GO:0002018 9.4 AGT AGTR1
18 regulation of renal sodium excretion GO:0035813 9.37 AGT AGTR1
19 renal sodium ion absorption GO:0070294 9.32 KLHL3 WNK4
20 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.26 AGT AGTR1
21 distal tubule morphogenesis GO:0072156 9.16 KLHL3 WNK4
22 post-translational protein modification GO:0043687 9.1 CAND1 COPS8 CUL3 KLHL3 RBX1 UBE2M
23 regulation of cellular process GO:0050794 8.96 WNK1 WNK4

Molecular functions related to Familial Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ubiquitin-protein transferase activity GO:0004842 9.46 CUL3 KLHL3 RBX1 UBE2M
2 ubiquitin protein ligase activity GO:0061630 9.43 CUL3 RBX1 UBE2M
3 chloride channel inhibitor activity GO:0019869 8.96 WNK1 WNK4
4 NEDD8 transferase activity GO:0019788 8.62 RBX1 UBE2M

Sources for Familial Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....